Skip to main content
OpenTrials
Completed

NCT Number: NCT01257763

Tolerability Study of the Application of a 3M Microstructure Transdermal System

The purpose of this study is to evaluate the safety and tolerability of an experimental device that introduces microscopic channels into the skin. Creating microscopic channels in the skin allows for better absorption of various medications applied to the skin, and this study will determine if the study device offers a tolerable method by which to introduce these holes. The study population will include 54 individuals, ages 18-74 years old, with a roughly equal distribution of skin colors. Each subject will have a total of three visits 24 hours apart from one another. The study device will be applied at the Baseline and Day 1 visits. At various timepoints before and after device application, skin assessments for irritation will be completed using a 7-point Skin Reaction Scale and photographs will be taken. Subjects will report pain associated with device application using a standardized pain scale. At the baseline visit, a member of the research staff will administer applications of the study device on the side of the subject's forehead, temple and the area below and to the side of the nose on randomly selected sides of the face. The side of the face at each location not receiving application of the study device will receive applications of a "dummy" device. Subjects will not be informed of which device is the study device and which is the "dummy" device. At the Day 1 visit, a member of the research staff will administer study device applications to the center of the subject's forehead. The subject will also self-apply the study device to the chin, under the instruction of the research staff member. At the Day 2 visit, final skin assessments will be made and the subject will be evaluated and treated for any persistent skin irritation. Differences in skin irritation between sites of study device application and "dummy" device application will be determined, as well as several other endpoints.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Northwestern University Feinberg School of Medicine, Department of Dermatology

Chicago, Illinois, 60611, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-74 years old
  • Subject in good health as determined by the investigator
  • Subject has the willingness and the ability to understand and provide informed consent and communicate with the investigator

Exclusion criteria

  • Subjects with active systemic or skin disease (including acne) or skin infection that could, in the opinion of the investigator, interfere with accurate study assessments
  • Baseline skin irritation as defined by a local skin reaction score greater than "0" at any of the application areas (Appendix 1)
  • Facial cosmetic procedures performed within 4 weeks of the baseline visit that may, in the opinion of the investigator, have an impact on skin assessment results†
  • Topical medications applied to the face within 2 weeks of the baseline visit that may, in the opinion of the investigator, have an impact on skin assessment results†
  • Subjects with skin disease such as atopic dermatitis, urticaria or dermatographism that may be exacerbated by device application †Subjects may enroll after a corresponding washout period

Treatment and study plan

Transdermal Microchannel Skin System

Device

A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.

Sham device

Device

The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.

Primary outcomes

  1. Local skin reaction scores

    Time frame: 48 hours

    Difference in median local skin reaction scores between Study Device side and Control side for any of the three facial application sites at any of the seven follow-up times.

  2. Median pain scores

    Time frame: 5 minutes

    Difference in median pain scores between Study Device side and Control side for any of the three facial application sites.

  3. Local skin reaction and reported pain central forehead

    Time frame: 24 hours

    Reported pain and change in skin irritation at the central forehead site.

  4. Local skin reaction score and reported pain chin

    Time frame: 24 hours

    Reported pain and change in skin irritation at the chin site.

Secondary outcomes

  1. Max difference in skin reaction score

    Time frame: 48 hours

    Maximal difference in local skin reaction score at any follow-up visit

  2. Subject questionnaire differences

    Time frame: 48 hours

    Reported differences in skin irritation or side-effects reported per patient questionnaire

  3. Differences between skin type groupings

    Time frame: 48 hours

    Differences in reported pain or changes in local skin reaction score at central forehead site between the 3 Fitzpatrick skin type groupings (I-II, III-IV and V-VI).

  4. Differences between age groups

    Time frame: 48 hours

    Differences in reported pain or changes in local skin reaction score at central forehead site between 3 age groupings (18-35, 36-60, 61-74).

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • 3M

Registry information

Official study title

Tolerability Study of the Application of a 3M Microstructure Transdermal System by Finger Pressure to the Face in Healthy Subjects Stratified by Age and Fitzpatrick Skin Type

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Dec 10, 2010
Registry last updated
Dec 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.